Advertisement

Phase III trial of Tecentriq in NSCLC meets DFS primary endpoint

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III IMpower010 study evaluating Tecentriq (atezolizumab) compared with best supportive care  met its primary endpoint of disease-free survival at the interim analysis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
Advertisement
Advertisement